Literature DB >> 12243316

The costs of exacerbations in chronic obstructive pulmonary disease (COPD).

F Andersson1, S Borg, S A Jansson, A C Jonsson, A Ericsson, C Prütz, E Rönmark, B Lundbäck.   

Abstract

Exacerbations are the key drivers in the costs of chronic obstructive pulmonary disease (COPD). The objective was to examine the costs of COPD exacerbations in relation to differing degrees of severity of exacerbations and of COPD. We identified 202 subjects with COPD, defined according to the BTS and ERS criteria. Exacerbations were divided into mild (self-managed), mild/moderate (telephone contact with a health-care centre and/or the use of antibiotics/systemic corticosteroids), moderate (health-care centre visits) and severe (emergency care visit or hospital admission). Exacerbations were identified by sending the subjects a letter inquiring whether they had any additional respiratory problems or influenza the previous winter. At least one exacerbation was reported by 61 subjects, who were then interviewed about resource use for these events. The average health-care costs per exacerbation were SEK 120 (95% C=39-246), SEK 354 (252-475), SEK 2111 (1673-2612) and SEK 21852 (14436-29825) for mild, mild/moderate, moderate and severe exacerbations, respectively. Subjects with impaired lung function experienced more severe exacerbations, which was also reflected in the cost of exacerbations per severity of the disease during the 4 1/2 month study period (ranging from SEK 224 for mild to SEK 13708 for severe cases, median SEK 940). Exacerbations account for 35-45% of the total per capita health-care costs for COPD. In conclusion, costs varied considerably with the severity of the exacerbation as well as with the severity of COPD. The prevention of moderate-to-severe exacerbations could be very cost-effective and improve the quality of life.

Entities:  

Mesh:

Year:  2002        PMID: 12243316     DOI: 10.1053/rmed.2002.1334

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  74 in total

1.  Comparison of clinico-physiologic and CT imaging risk factors for COPD exacerbation.

Authors:  Jung-Wan Yoo; Yoonki Hong; Joon Beom Seo; Eun Jin Chae; Seung Won Ra; Ji-Hyun Lee; Eun Kyung Kim; Seunghee Baek; Tae-Hyung Kim; Woo Jin Kim; Jin Hwa Lee; Sang-Min Lee; Sangyeub Lee; Seong Yong Lim; Tae Rim Shin; Ho Il Yoon; Seung Soo Sheen; Jae Seung Lee; Jin Won Huh; Yeon-Mok Oh; Sang-Do Lee
Journal:  J Korean Med Sci       Date:  2011-11-29       Impact factor: 2.153

2.  Vitamin D levels and risk of acute exacerbations of chronic obstructive pulmonary disease: a prospective cohort study.

Authors:  Ken M Kunisaki; Dennis E Niewoehner; John E Connett
Journal:  Am J Respir Crit Care Med       Date:  2011-11-10       Impact factor: 21.405

Review 3.  Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: a review of the evidence and methodological issues.

Authors:  Maureen P M H Rutten-van Mölken; Lucas M A Goossens
Journal:  Pharmacoeconomics       Date:  2012-04       Impact factor: 4.981

Review 4.  Assessment of progression of COPD: report of a workshop held in Leuven, 11-12 March 2004.

Authors:  M Decramer; R Gosselink; M Rutten-Van Mölken; J Buffels; O Van Schayck; P-A Gevenois; R Pellegrino; E Derom; W De Backer
Journal:  Thorax       Date:  2005-04       Impact factor: 9.139

5.  Doxycycline Added to Prednisolone in Outpatient-Treated Acute Exacerbations of COPD: A Cost-Effectiveness Analysis Alongside a Randomised Controlled Trial.

Authors:  Aureliano Paolo Finch; Patricia van Velzen; Gerben Ter Riet; Peter J Sterk; Jan M Prins; Judith E Bosmans
Journal:  Pharmacoeconomics       Date:  2019-05       Impact factor: 4.981

6.  Azithromycin for prevention of exacerbations of COPD.

Authors:  Richard K Albert; John Connett; William C Bailey; Richard Casaburi; J Allen D Cooper; Gerard J Criner; Jeffrey L Curtis; Mark T Dransfield; Meilan K Han; Stephen C Lazarus; Barry Make; Nathaniel Marchetti; Fernando J Martinez; Nancy E Madinger; Charlene McEvoy; Dennis E Niewoehner; Janos Porsasz; Connie S Price; John Reilly; Paul D Scanlon; Frank C Sciurba; Steven M Scharf; George R Washko; Prescott G Woodruff; Nicholas R Anthonisen
Journal:  N Engl J Med       Date:  2011-08-25       Impact factor: 91.245

7.  Present and future costs of COPD in Iceland and Norway: results from the BOLD study.

Authors:  R Nielsen; A Johannessen; B Benediktsdottir; T Gislason; A S Buist; A Gulsvik; S D Sullivan; T A Lee
Journal:  Eur Respir J       Date:  2009-04-08       Impact factor: 16.671

Review 8.  Role of macrolide therapy in chronic obstructive pulmonary disease.

Authors:  Fernando J Martinez; Jeffrey L Curtis; Richard Albert
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

Review 9.  Newer fluoroquinolones in the treatment of acute exacerbations of COPD.

Authors:  Amit Patel; Robert Wilson
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006

10.  Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial.

Authors:  Sanjay Sethi; Paul W Jones; Marlize Schmitt Theron; Marc Miravitlles; Ethan Rubinstein; Jadwiga A Wedzicha; Robert Wilson
Journal:  Respir Res       Date:  2010-01-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.